SZLS Stock Overview
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in the United States and Canada.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
StageZero Life Sciences Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.07 |
| 52 Week High | CA$0.28 |
| 52 Week Low | CA$0.055 |
| Beta | 0.96 |
| 1 Month Change | 16.67% |
| 3 Month Change | -12.50% |
| 1 Year Change | -70.21% |
| 3 Year Change | -80.56% |
| 5 Year Change | -94.17% |
| Change since IPO | -99.71% |
Recent News & Updates
Shareholder Returns
| SZLS | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 7.7% | 3.8% | 0.7% |
| 1Y | -70.2% | -0.2% | -0.4% |
Return vs Industry: SZLS underperformed the Canadian Biotechs industry which returned -0.2% over the past year.
Return vs Market: SZLS underperformed the Canadian Market which returned -0.4% over the past year.
Price Volatility
| SZLS volatility | |
|---|---|
| SZLS Average Weekly Movement | 11.1% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 9.9% |
| 10% most volatile stocks in CA Market | 19.5% |
| 10% least volatile stocks in CA Market | 3.9% |
Stable Share Price: SZLS is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: SZLS's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 80 | James Howard-Tripp | https://www.stagezerolifesciences.com |
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in the United States and Canada. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company’s lead product is Aristotle, a multi-cancer panel test for simultaneously screening for various cancers from a single sample of blood with high sensitivity and specificity for each cancer.
StageZero Life Sciences Ltd. Fundamentals Summary
| SZLS fundamental statistics | |
|---|---|
| Market Cap | CA$7.38m |
| Earnings (TTM) | -CA$5.64m |
| Revenue (TTM) | CA$6.19m |
1.2x
P/S Ratio-1.3x
P/E RatioIs SZLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SZLS income statement (TTM) | |
|---|---|
| Revenue | US$4.62m |
| Cost of Revenue | US$4.74m |
| Gross Profit | -US$122.57k |
| Other Expenses | US$4.09m |
| Earnings | -US$4.21m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.04 |
| Gross Margin | -2.65% |
| Net Profit Margin | -91.17% |
| Debt/Equity Ratio | 104.6% |
How did SZLS perform over the long term?
See historical performance and comparison